Major histocompatibility class II HLA-DRα gene expression in thyrocytes:: Counter regulation by the class II transactivator and the thyroid Y box protein

被引:24
|
作者
Montani, V
Taniguchi, S
Shong, MH
Suzuki, K
Ohmori, M
Giuliani, C
Napolitano, G
Saji, M
Fiorentino, B
Reimold, AM
Ting, JPY
Kohn, LD
Singer, DS
机构
[1] NIDDKD, Cell Regulat Sect, Metab Dis Branch, NCI,NIH, Bethesda, MD 20892 USA
[2] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA
[3] Johns Hopkins Univ, Dept Surg, Baltimore, MD 21287 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Med, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA 02115 USA
[7] Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.1210/en.139.1.280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aberrant expression of major histocompatibility complex (MHC) class II proteins on thyrocytes; which is associated with autoimmune thyroid disease, is mimicked by gamma-interferon (gamma-IFN). To define elements and factors that regulate class II gene expression in thyrocytes and that might be involved in aberrant expression, we have studied gamma-IFN-induced HLA-DR alpha gene expression in rat FRTL-5 thyroid cells. The present report shows that class II expression in FRTL-5 thyrocytes is positively regulated by the class II transactivator (CIITA), and that CIITA mimics the action of gamma-IFN. Thus, as is the case for gamma-IFN, several distinct and highly conserved elements on the 5'-flanking region of the HLA-DR alpha gene, the S, X-1, X-2, and Y boxes between -137 to -65 bp, are required for class II gene expression induced by pCIITA transfection in FRTL-5 thyroid cells. CIITA and gamma-IFN do not cause additive increases in HLA-DR alpha gene expression in FRTL-5 cells, consistent with the possibility that CIITA is an intermediate factor in the gamma-IFN pathway to increased class II gene expression. Additionally, gamma-IFN treatment of FRTL-5 cells induces an endogenous CIITA transcript; pCIITA transfection mimics the ability of gamma-IFN treatment of FRTL-5 thyroid cells to increase the formation of a specific and novel protein/DNA complex containing CBP, a coactivator of CRE binding proteins important for cAMP-induced gene expression; and the action of both gamma-IFN and CIITA to increase class II gene expression and increase complex formation is reduced by cotransfection of a thyroid Y box protein, which suppresses MHC class I gene expression in FRTL-5 thyroid cells and is a homolog of human YB-1, which suppresses MHC class II expression in human glioma cells. We conclude that CIITA and TSH receptor suppressor element binding protein-1 are components of the gamma-IFN-regulated transduction system which, respectively, increase or decrease class II gene expression in thyrocytes and may, therefore, be involved in aberrant class II expression associated with autoimmune thyroid disease.
引用
收藏
页码:280 / 289
页数:10
相关论文
共 50 条
  • [1] EXPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS-II-ANTIGENS AND HLA-DR INCOMPATIBILITY
    OBA, S
    TOMA, H
    TAKAHASHI, K
    OTA, K
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 323 - 324
  • [2] Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer
    Jo, Young Suk
    Lee, Jun Choi
    Li, Shengjin
    Choi, Yun-Sun
    Bai, Youn-Sun
    Kim, Yun-Jeung
    Lee, Ihn-Suk
    Rha, So Young
    Ro, Heung-Kyu
    Kim, Jin-Man
    Shong, Minho
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (04) : 785 - 790
  • [3] Regulation of MHC class II gene expression by the class II transactivator
    Reith, W
    LeibundGut-Landmann, S
    Waldburger, JM
    NATURE REVIEWS IMMUNOLOGY, 2005, 5 (10) : 793 - 806
  • [4] Regulation of MHC class II gene expression by the class II transactivator
    Walter Reith
    Salomé LeibundGut-Landmann
    Jean-Marc Waldburger
    Nature Reviews Immunology, 2005, 5 : 793 - 806
  • [5] Neuronal expression of class II major histocompatibility complex (HLA-DR) in 2 cases of Pick disease
    Hollister, RD
    Xia, MQ
    McNamara, MJ
    Hyman, BT
    ARCHIVES OF NEUROLOGY, 1997, 54 (03) : 243 - 248
  • [6] Class II transactivator: Mastering the art of major histocompatibility complex expression
    Harton, JA
    Ting, JPY
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (17) : 6185 - 6194
  • [7] Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator
    Kretsovali, A
    Agalioti, T
    Spilianakis, C
    Tzortzakaki, E
    Merika, M
    Papamatheakis, J
    MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) : 6777 - 6783
  • [8] Histone Acetylation and the Regulation of Major Histocompatibility Class II Gene Expression
    Suzuki, K.
    Luo, Y.
    CHROMATIN REMODELLING AND IMMUNITY, 2017, 106 : 71 - 111
  • [9] Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: Opposite effects of interferon and methimazole
    Montani, V
    Shong, MH
    Taniguchi, S
    Suzuki, K
    Giuliani, C
    Napolitano, G
    Saito, J
    Saji, M
    Fiorentino, B
    Reimold, AM
    Singer, DS
    Kohn, LD
    ENDOCRINOLOGY, 1998, 139 (01) : 290 - 302
  • [10] The transcriptional regulation of Class II Transactivator and its role in aberrant Major Histocompatibility Complex II expression in metastatic melanoma
    Osborn, Jodi Lynn
    Greer, Susanna F.
    FASEB JOURNAL, 2011, 25